HOME >> MEDICINE >> NEWS
Blocking enzyme found to ease anxiety without causing sedation

The trouble with most anti-anxiety drugs is that they tend to sedate, not just relax. A research team led by scientists at UCSF's Ernest Gallo Clinic and Research Center has shown that de-activating a common enzyme in neurons reduces anxiety without inducing sedation. The study in mice suggests a new route to treat anxiety while avoiding sedating and possibly addicting effects.

The research, published in the October issue of The Journal of Clinical Investigation, also showed that blocking the enzyme reduced levels of stress hormones. The same issue of the journal includes a commentary on the research (Anxiolytic Drug Targets: Beyond the Usual Suspects) by Joshua A. Gordon of Columbia University's Center for Neurobiology and Behavior.

Anti-anxiety drugs such as Valium often leave people sedated, less capable at mental tasks, and can become addicting, whereas drugs without these side effects -- such as some antidepressants -- may not reduce anxiety as well, said Robert Messing, MD, UCSF professor of neurology at the Gallo Research Center and senior author on the paper.

But in the new study, mice lacking the enzyme showed reduced anxiety while maintaining normal levels of alertness and learning abilities, the researchers reported.

The enzyme, known as protein kinase C epsilon (PKC epsilon), is present in many neurons in the brain, but its role is not well known. Its ability to affect anxiety but not sedation may stem from indirect, rather than direct action, the researchers found.

When the neurotransmitter GABA binds to proteins on the surface of many neurons, known as GABA-A receptors, the neurons become less active, which tends to reduce anxiety. Drugs such as Valium act by increasing the action of GABA at the GABA-A receptors. A group of brain molecules derived from progesterone, known as neurosteroids, also act to increase the action at the GABA-A receptor, and thereby reduce anxiety. But PKC epsilon appears to make the GA
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415 476-2557
University of California - San Francisco
2-Oct-2002


Page: 1 2

Related medicine news :

1. Blocking molecules protects health of implants
2. Blocking selected neurotransmitter activity may decrease alcohol consumption
3. Blocking immune response to spinal cord injury can improve chances for recovery
4. Blocking pathway overcomes tumor vessel resistance to radiation
5. Blocking adhesion protein may reduce lung damage from radiation
6. Blocking gene may reduce lung scarring caused by radiation therapy
7. Scientists discover enzyme crucial to the transportation of proteins within cells
8. Scientists discover enzyme crucial to HIV replication
9. Study shows coenzyme Q10 may prevent migraine
10. New information about heart enzymes could lead to better treatments
11. Researchers identify enzyme that may turn fleeting experience into lasting memory

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Blocking enzyme found ease anxiety without causing sedation

(Date:7/30/2014)... teaching hospital in Ireland has shown than many of them ... minimise the risk of entrapment. The report, published online in ... need for careful selection of patients for whom bedrails are ... and maintenance of hospital bed systems. , Bedrails are commonly ... However, although the risk for any individual is extremely low, ...
(Date:7/30/2014)... July 30, 2014 Victory Medical ... proud to announce the launch of a pediatric unit ... general surgery. The doctors working in the pediatrics departments ... infants, children, and adolescents. Dr. Timothy Cole, Dr. Dale ... McDuffie, Dr. Neelesh Mehendale, and Dr. Nicholas Peiffer lead ...
(Date:7/30/2014)... 30, 2014 Dialogic Inc. ... announced that DollarPhone, the largest privately owned calling ... Dialogic® ControlSwitch™ softswitch to offer enhanced ... portability (LNP) to both its wholesale and prepaid ... is able to power DollarPhone’s network infrastructure, allowing ...
(Date:7/30/2014)... 30, 2014 A formal complaint ... Office against the maker of the dialysis products ... Medical Care defrauded the state, its residents, physicians ... dialysates, before they were recalled in 2012. There ... these products pending in the U.S. District Court, ...
(Date:7/30/2014)... -- ,Middle-aged adults with a history of alcohol abuse ... develop severe memory problems later in life, according to ... findings could help doctors identify those at risk for ... drinking. "We already know there is an association ... -- that understanding is based on asking older people ...
Breaking Medicine News(10 mins):Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2
(Date:7/29/2014)... 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... two healthcare conferences during the third quarter, the 2014 ... Global Healthcare 2014 Conference.  Alexza,s corporate presentation will be ... on each event are below: , 2014 ... in Boston , MA.  The format ...
(Date:7/29/2014)... Inc. (NYSE: CVD ) today reported results ... revenue was $639 million, representing 8.0% growth from the ... company reported earnings of $0.29 per diluted share in ... per diluted share of $0.95, up 21.5% over the ... impairment charges totaling $52.6 million, or $0.61 per share, ...
(Date:7/29/2014)... New technology in the form of a ... see and assess brain tissue more clearly while treating ... who released their findings today at the Society of ... Colorado Springs, CO. ... a specialty that facilitates stroke treatment by navigating a ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
Cached News: